Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT02426281 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT02426281
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02426281 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Samsung Medical Center
Phase
Phase 2
Overall status
Completed
Start date
June 4, 2015
Completion date
September 30, 2022
Enrollment
111 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic ductal adenocarcinoma